Navigation Links
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Date:8/1/2008

---------

MBP8298 (dirucotide) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 (dirucotide) is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of MBP8298 is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The apparent mechanism of action of MBP8298 (dirucotide) is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 (dirucotide) for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 (dirucotide) has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 year
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: ... develops and commercializes proprietary technologies and products for ... has received approval from the TSX Venture Exchange ... share purchase warrants ("the Warrants") of the Company, ... May 2013 private placement financing. Each ...
(Date:4/17/2015)... 17, 2015  US-Australian drug discovery company, Novogen, today ... Understanding with the Feinstein Institute for Medical Research ... to collaborate with the objective of developing ... collaboration brings together the drug discovery expertise of ... the Feinstein Institute in neurosciences and oncology. ...
(Date:4/17/2015)... 2015 LC Sciences LLC, a ... today that it is seeking beta testers for ... PCR based targeted sequencing technology. The system offers ... enables accurate detection of rare variants. It utilizes ... The company will collaborate with beta testers to ...
(Date:4/16/2015)... Spirax Sarco, the leader in ... newly designed, state-of-the-art website in the first quarter ... promotes the Spirax Sarco brand, company capabilities, and ... a site visitor might be looking for including ... serviced, the latest company news, careers, and much ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Spirax Sarco website has a new look 2
... BEIJING, July 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... in China, announced today,that its Annual General Meeting originally scheduled ... , At the July 16, 2009 ... outstanding shares was not present. In accordance with Antigua,law, the ...
... week are marking major breakthroughs in the effort to ... than 200 million people worldwide and causes long-term debilitating ... documents a multinational success, led by a team at ... the genome of the Schistosoma mansoni blood fluke, which ...
... , , , ... that it had closed its series A financing round. The infusion of capital ... that converts a wide variety of cellulosic materials (such as algae, plants and ... , As part of the agreement, the lead investor has joined ...
Cached Biology Technology:Sinovac Adjourns 2008 Annual General Meeting 2UCSF researchers help crack parasite genome, identify drug leads 2UCSF researchers help crack parasite genome, identify drug leads 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... the first researchers to study the deadly link between ... Association lifetime achievement award today at a ceremony in ... endocrinologist James Sowers, MD, recognizes his more than 30 ... The Irvine Page-Alva Bradley Lifetime Achievement Award in ...
... it they,re very good at what they do. But ... out inspection work in oily or dangerous environments, or in ... they,re one of the fastest and most maneuverable creatures on ... speeds due to their streamlined bodies and a finely tuned ...
... , New Rochelle, NY, September 19, 2012 Many ... will largely be based on the field of ... News ( GEN ) ( http://genengnews.com ). ... larger arrays of biosamples, demand is exceeding supply, ...
Cached Biology News:Pioneering researcher receives Heart Association Lifetime Achievement Award 2Pioneering researcher receives Heart Association Lifetime Achievement Award 3Robotic tuna is built by Homeland Security 2
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Purified anti-human CD182 (CXCR2)...
Biology Products: